// App-Quantinova.ai

696 : Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial

Researchers

Presenter

  • Kerry Reynolds

Principal Investigators

  • Meghan Mooradian

  • Daniel Zlotoff

  • Paul Ridker

  • Tomas Neilan

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Ventricular arrhythmias

  • Deep vein thrombosis

  • Cardiac arrest

  • Pulmonary embolism

  • Venous thrombosis

  • Myocardial injury

  • Cardiogenic shock

  • Congestive heart failure

  • Viral myocarditis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Methylprednisolone

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved